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400 063, India.Aim: Insulin resistance is characterized by alterations in insulin signaling components thereby resulting
in reduced glucose uptake. The mechanistic role of (3b)-stigmast-5-en-3-ol in augmenting glucose uptake
to overcome insulin resistance is deciphered in this study.
Main methods: L6 myotubes, rat skeletal muscle model have been used to check the effect of (3b)-stig-
mast-5-en-3-ol, a plant phytosterol isolated from the ethyl acetate extract of Adathoda vasica on glucose
transport. The inﬂuence of (3b)-stigmast-5-en-3-ol on various cellular targets of insulin signaling cascade
has been evaluated using inhibitors on glucose uptake as well as gene and protein expression to unravel
the mechanistic action in triggering glucose uptake.
Results: (3b)-stigmast-5-en-3-ol promoted glucose uptake in a dose dependent manner under insulin
resistant condition. As assessed by inhibitor studies using Genistein (IRTK inhibitor) and Wortmannin
(PI3K inhibitor), gene expression and protein expression studies using speciﬁc primers and antibodies,
an activation of IR-b, IRS-1, PI3K, AKT/PKB, PKC by both the crude and (3b)-stigmast-5-en-3-ol were
observed. This suggested that (3b)-stigmast-5-en-3-ol induced glucose uptake functions through the
PI3K dependent pathway in L6 myotubes. Both, the crude and (3b)-stigmast-5-en-3-ol activates GLUT
4 transport (evident from increased mRNA levels and redistribution of GLUT4 from intracellular mem-
brane to plasma membrane through translocation studies). Confocal microscopy revealed a substantial
increase in redistribution of FITC tagged GLUT4 throughout the cells.
Conclusion: Our results emphasize the insulin-like effect of (3b)-stigmast-5-en-3-ol in stimulating glu-
cose transport in vitro and provide evidence in its beneﬁcial role possessing antidiabetic property apart
from its existing cholesterol lowering efﬁcacy.
 2009 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction
The main pathophysiological defect of type 2 diabetes is insulin
resistance, a decrease in cellular response to insulin. This includes
impairment in the insulin signaling pathway leading to a failure of
the insulin stimulated glucose uptake in targeted tissues like mus-
cle and fat. In muscle cells, this is due to the inability of the insulin
to stimulate the translocation of GLUT4 (Glucose transporter 4) to
plasma membrane [1]. An effective glucose uptake mechanism oc-
curs when insulin binds to its tyrosine kinase receptor, leading to
tyrosine phosphorylation of insulin receptor substrate (IRS)-1 pro-
tein followed by the activation of Src homology domain protein
like Phosphatidyl inositide kinase (PI3K). The downstream targetsellitus. Published by Elsevier Ltd.
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Oof PI3K include AKT/PKB (Protein Kinase B) and PKC (Protein Kinase
C), whose activation/phosphorylation triggers the translocation of
GLUT4 from intracellular pool to the plasma membrane [2,3]. Nat-
ural products provide a wide range of therapeutics for many dis-
eases and infections. Traditional knowledge driven drug
development owes safe drug discovery, and facilitates the creation
of new chemical entities [4].
Adathoda vasica (L.) Nees (family Acanthaceae) is a well-known,
traditionally used plant in Ayurveda and Unani medicine [5]. Many
reports emphasize the medicinal value of A. vasica and its usage for
treating diseases such as bronchitis, asthma, fever, jaundice, vom-
iting, leucoderma, tumors and diabetes [6]. The antitussive effect
[7] and the antioxidant property [8] of this plant are established.
World Health Organisation has reported A. vasica as a recom-
mended medicinal plant with therapeutic utility and non-toxic,
with greater usage in primary health care in both adults and chil-
dren [5]. The ethanolic extracts from the leaves of A. vasica showed
hypoglycemic activity after oral administration in rats and rabbits
[9]. The major constituents of A. vasica are essential oil, steroids
and quinazoline alkaloids like vasicine, vasicinone, vasicinolone,pen access under CC BY-NC-ND license.
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cone, kaempferol and (3b)-stigmast-5-en-3-ol [5].
(3b)-stigmast-5-en-3-ol is a plant phytosterol found commonly
in many plants. Other common names of (3b)-stigmast-5-en-3-ol
includes Betasitosterol, (3b)-stigmast-5-en-3-ol, 22:23-dihydro-
stigmasterol, alpha-dihydrofucosterol, cinchol, cupreol, rhamnol,
quebrachol and (3b)-stigmast-5-en-3-ol. The anti-proliferative ef-
fect of (3b)-stigmast-5-en-3-ol, has been investigated using
in vitro models [10] and also has been documented for its choles-
terol lowering effect [11]. Hwang and co-workers [12] reported
on the enhancement of glucose uptake by betasitosterol through
LKB1-mediated AMPK activation in in vitro model. However its
mechanistic role in triggering insulin signaling cascade for aug-
menting glucose transport needs exploration. Against this back-
ground, the present study aims at ﬁnding the mechanistic action
of (3b)-stigmast-5-en-3-ol on the insulin signaling cascade using
L6 myotubes, a well established skeletal muscle model for evaluat-
ing the anti-diabetic potential.2. Materials and methods
2.1. Chemicals and reagents
Unless otherwise stated, materials were obtained from Sigma–
Aldrich, St. Louis. All cell culture solutions and supplements were
purchased from Life Technologies Inc. (Gaithersburg, MD, USA).
2-Deoxy D-[1-3H] glucose and hybond C membrane were obtained
from Amersham Pharmacia Biotech, (Buckinghamshire, UK).
DMEM, Trizol reagent and MMLV reverse transcriptase, dNTP,
Taq polymerase and synthesized primers were obtained from GIB-
CO BRL, (Carlsbad, CA, USA). Wortmannin, Mowiol, anti-GLUT4 and
anti-actin antibodies were obtained from Calbiochem (Darmstadt,
Germany). Rosiglitazone was a kind gift from Dr. Reddy’s Laborato-
ries, Hyderabad. Primers were synthesized from GIBCO BRL (Carls-
bad, CA, USA). IR, Phospho-IR, IRS-1, phospho-IRS-1 antibodies
were procured from Santa cruz. Anti-phospho AKT and p85 PI3K
were obtained from BD Pharmingen (San Diego, CA, USA) Alkaline
phosphatase-conjugated secondary antibodies, Horse radish per-
oxidise-conjugated secondary antibodies and anti-goat IgG-FITC
were obtained from Santa Cruz Biotechnology, USA. All other HPLC
and analytical grade solvents and silica gel required for column
puriﬁcation were obtained from SISCO Research Laboratories,
India.
2.2. Cell culture of L6 myotubes
L6, a differentiating monolayer myoblast culture (obtained from
ATCC-CRL-1458) was maintained in DMEM (Dulbecco’s modiﬁed
Eagle’s medium) with 10% FBS and supplemented with penicillin
(120 units/mL), streptomycin (75 lg/mL), gentamycin (160 lg/
mL) and amphotericin B (3 lg/mL) in a 5% CO2 environment. For
differentiation, the L6 cells were transferred to DMEM with 2%
FBS for 4 days, post-conﬂuence. The extent of differentiation was
established by observing the multinucleation of cells. Once differ-
entiated, the cells were incubated 24 h with high glucose medium
(the above mentioned DMEM medium with a supplement of
25 mM/L glucose) for the cells to acquire an insulin resistant state
[13,14].
2.3. Measurement of 2-deoxy-D-[1-3H] glucose uptake
L6 myoblasts grown in 24-well plates (BD Falcon) were serum
starved for 5 h and were incubated with the plant extracts and
compound for 24 h and subjected to glucose uptake assay as re-
ported [15]. Glucose uptake values were corrected for non-speciﬁcuptake in the presence of 10 lM cytochalasin B, (5–8% of total up-
take). All the assays were performed in duplicates and repeated
three times, for concordance. Results have been expressed as a per-
centage of glucose uptake with respect to the solvent control. Ros-
iglitazone (50 lM) was used as the positive control.
For inhibitor studies, L6 myotubes were treated with Genistein
50 lM [16] and Wortmannin 100 nM [17], 30 min prior to the
incubation with the plant extracts and compound followed by
the glucose uptake assay.2.4. Extraction of A. vasica ethyl acetate leaf extract and isolation of
(3b)-stigmast-5-en-3-ol
The leaves of A. vasica after authentication were dried, pow-
dered and sequentially extracted using organic solvents including
hexane, dichloromethane, ethyl acetate and methanol by cold mac-
eration as previously reported [18]. All the extracts were checked
for glucose uptake efﬁcacy. The ethyl acetate extract showed max-
imum glucose uptake activity compared to the other extracts, and
was selected for puriﬁcation. A Column of silica gel 100–200 mesh
size was packed with hexane. The sample (active ethyl acetate ex-
tract) was loaded as dried slurry of silica gel (1:20 by ratio). The
column was eluted with a gradual increase in polarity, using ethyl
acetate. The eluted fractions were tested for glucose uptake activ-
ity. The active fraction was puriﬁed by additional column chroma-
tography and its purity established by HPLC. The structure of the
active compound was determined by 1H, 13C, DEPT 90, DEPT 135,
COSY and ESI-MS. The compound was structurally characterized
as (3b)-stigmast-5-en-3-ol with elemental composition and mass
of C29H50O and 414 respectively.2.5. Reverse transcriptase-polymerase chain reaction
RT-PCR was carried out as described previously [19]. The iso-
lated mRNA were converted to cDNA by reverse transcription
and subjected to PCR using speciﬁc primers as follows: IRTK, F: 50
ATC TGG ATC CCC CTG ATA ACT GTC 30; R: 50 ATG TGG GTG TAG
GGG ATG TGT TCA 30 (Genbank accession number NM_017071.1),
GLUT 4, F: 50 CGG GAC GTG GAG CTG GCC GAG GAG 30; R: 50 CCC
CCT CAG CAG CGA GTG A 30 [20], PI3K p85a regulatory subunit,
F: 5’ TGA CGC TTT CAA ACG CTA TC 30; R : 50 CAG AGA GTA CTC
TTG CAT TC 30 [21], PKC a , F: 50 ACC TGA AGC TGG ACA ACG 30;
R: 50 GCT ACT CCT ACG GTA TTT 30(Genbank accession number
NM 001105713.1) and GAPDH, F: 50 CCA CCC ATG GCA AAT TCC
ATG GCA 30; R: 50 TCT AGA CGG CAG GTC AGG TCC ACC 30 [22].
PCR products were resolved in agarose gels, stained with ethidium
bromide and photographed. Rosiglitazone and Insulin were used at
50 lM and 100 nM respectively to determine the efﬁcacy. The
expression levels were quantitated by scanning on a gel documen-
tation and analysis system (Chemi Imager 4400, Alpha Innotech
Corporation).2.6. Immunoprecipitation
L6. myotubes were treated with optimum concentrations of
A. vasica ethyl acetate extract and (3b)-stigmast-5-en-3-ol for
indicated time periods after serum starvation for 8 h. The cell ly-
sates were prepared as reported [23]. The lysates were immuno-
precipitated using Protein A Sepharose beads with speciﬁc
phosphorylated forms of anti-IRb and anti-IRS-1 [24]. The immu-
noprecipitated lysates were then transferred onto nitrocellulose
membrane.
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The immunoblots were probed with the respective primary
antibody (IR-b, IRS-1, p85PI3K, pAKT and AKT), followed by speciﬁc
secondary antibody and visualized using a chromogenic substrate.
The density of the protein bands were quantitated by scanning the
blots on a gel documentation and analysis system (Chemi Imager
4400, Alpha Innotech Corporation).
2.8. Subcellular membrane fractionation
Subcellular membrane fractions were obtained using the differ-
ential ultra-centrifugation method, as described previously [15],
with minor modiﬁcations. Brieﬂy, L6 myotubes after treatment
with plant extract and compound were washed and resuspended
in buffer I (250 mM/L Sucrose, 5 mM NaN3, 20 mM HEPES,
200 lM/L PMSF, 1 lM/L Pepstatin, 1 lM/L Aprotinin and 2 mM/L
EGTA, pH 7.4). Cell lysate was homogenized using 20 strokes of a
Dounce homogenizer (0.5 cycles, 10 pulses; 2 min each and lag
time of 1 min for each pulse). The cell homogenates were centri-
fuged at 750g for 5 min at 4 C to remove cell debris. The Plasma
membrane (PM) fraction was obtained by centrifugation of the
resulting supernatant at 30,000g for 40 min at 4 C. The resultant
pellet was resuspended in Buffer I to constitute the PM fraction.
Supernatant was removed and centrifuged at 100,000g for
75 min at 4 C to generate the cytosol fraction from the obtained
pellet. The light microsome (LM) pellet resuspended in buffer I
and PM fraction were assayed for soluble protein content by Brad-
ford’s assay. 50 nucleosidase and NADPH cyt-c reductase were used
as the marker enzymes for PM and LM respectively. The membrane
fractions were subjected to electrophoresis on 10% SDS-PAGE,
transferred to nitrocellulose membranes, and immunoblotted with
anti-GLUT4 antibody.
2.9. Immunoﬂuorescence analysis and confocal microscopy
L6 myotubes (60% of differentiated cells) grown on coverslips,
after treatment with the crude and pure at indicated time points
were washed with 1X PBS. The cells were ﬁxed with 3.7% formal-
dehyde in PBS for 10 min at room temperature, and permeabilized
in PBS containing 0.01% Triton-X for 10 min. The cells were then
blocked with 3% FBS in PBS for 10 min and incubated with anti-
goat GLUT 4 antibody (1:250 dilution, sc-1607) in 3% FBS in PBS
for 1 h at 4 C. This was followed by incubation with 1:100 dilution
of donkey anti-goat IgG-FITC (sc-2024) for 1 h at 4 C. All coverslips
were washed with PBS thrice during each incubation step andFig. 1. Comparative analysis of Adathoda vasica ethyl acetate extract and (3b)-stigmast-5
structure of (3b)-stigmast-5-en-3-ol were displayed. The results were expressed as pe
Rosiglitazone (50 lM) showed 132.2% uptake. The values are mean of ±S.E., n = 3 in dupﬁnally mounted on slide with Mowiol for confocal microscopy.
Fluorescence was measured with Leica TCS SP2 inverted spectral
confocal microscope (Germany) equipped with 60 objective with
excitation and emission of 468 nm and 543 nm (for FITC)
respectively.
2.10. Statistical analysis
Mean ± SEM were represented. Statistically signiﬁcant differ-
ences between groups were analysed using Student’s t-test. The
statistical signiﬁcance was evaluated using one way ANOVA to
determine differences among groups and Tukey’s multiple com-
parison tests to determine signiﬁcant differences between groups.
These were applied using SPSS version 11.0 (SPSS, Cary, NC, USA)
and the criterion for statistical signiﬁcance was P < 0.05.
3. Results
3.1. (3b)-stigmast-5-en-3-ol stimulates glucose uptake in L6 myotubes
To examine the effect of ethyl acetate extract and its bioactive
compound, (3b)-stigmast-5-en-3-ol on glucose transport , L6 myo-
tubes were treated with varying concentrations of the extract and
the compound at three different time points (12, 24 and 36 h). A
dose- and time-dependent increase in glucose uptake activity
was observed on treatment with the crude extract as well as the
puriﬁed compound. At 24 h, maximal effect was achieved which
sustained even at 36 h (data not shown for 12 and 36 h). The ethyl
acetate extract and (3b)-stigmast-5-en-3-ol signiﬁcantly stimu-
lated basal glucose uptake and the optimal dose with maximum
activity was found to be 1 lg/mL (102.9% of vehicle control,
p < 0.05) and 100 ng/ml (113.6% of vehicle control, p < 0.05) respec-
tively (Fig. 1), and these concentrations were used for further
studies.
3.2. Activation of IR-b, IRS-1, PI3K, AKT/PKB and PKC by (3b)-stigmast-
5-en-3-ol in L6 myotubes
To determine whether ethyl acetate extract and (3b)-stigmast-
5-en-3-ol are capable of modulating activation of insulin receptor,
gene and protein expression studies were performed. The ethyl
acetate extract and (3b)-stigmast-5-en-3-ol increased the mRNA
levels of Insulin receptor from 6 h onwards, and a signiﬁcant in-
crease in expression was observed at 18 h (p < 0.05) as shown in
Fig. 2a and b. In addition, the expression of phospho-speciﬁc IR-b
and IRS-1 were also checked. Our results revealed the increase of-en-3-ol on 2-deoxy-D-[1-3H] glucose uptake. Dose response analysis at 24 h and the
rcentage glucose uptake with respect to the vehicle control. The positive control,
licates. (*), P < 0.05 as compared with vehicle control group.
Fig. 2. (a) Effect of Adathoda vasica ethyl acetate extract and (3b)-stigmast-5-en-3-ol on IRTK, PI3K, PKC and GLUT4 mRNA expression. L6 myotubes were incubated with
Insulin (100 nM), Rosiglitazone (50 lM), crude (1 lg/mL) or pure (100 ng/mL) at indicated time points for each marker. Lane 1 denotes the 100 bp marker, Lanes 2–4 indicates
untreated cells (control), Rosiglitazone and Insulin respectively. Lanes 5–7 and 8–10 indicates 6 h, 18 h and 24 h of Adathoda vasica crude treated cells and (3b)-stigmast-5-
en-3-ol treated cells respectively. Lane 11 shows the PCR negative control. GAPDH transcripts were used as the internal control. Insulin serves as a positive control for IRTK,
PI3K, PKC and GLUT4 expressions. Rosiglitazone serves as a positive control for GLUT4 and negative control for IRTK, PI3K and PKC expressions. All the samples were run on
the same gel and the dividing lines are for better understanding of the data. (b) Semi-quantitative analysis of IRTK, PI3K and GLUT4 mRNA transcripts upon treatment with
Adathoda vasica ethyl acetate extract and (3b)-stigmast-5-en-3-ol. The signaling intensities of IRTK, PI3K, PKC and GLUT4 transcripts were quantiﬁed using densitometric
scanning. The signaling intensities were quantiﬁed arbitrarily. Bars represent mean of ±S.E., n = 3 and a representative agarose gel is shown here. (*), P < 0.05 as compared
with untreated control group.
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acetate extract and (3b)-stigmast-5-en-3-ol, as shown in Fig. 3a. A
representative densitometric scanning for semi-quantitative anal-
ysis is shown in Fig. 3b. Taken together, these data suggested that
the ethyl acetate extract and (3b)-stigmast-5-en-3-ol activated IR-
b and IRS-1 similar to the positive control, insulin.
To examine whether (3b)-stigmast-5-en-3-ol stimulates glu-
cose transport in a PI3K dependent manner, RT-PCR analysis and
phospho-detect p85 PI3K were employed. As shown in Fig. 2a,
treatment with crude and (3b)-stigmast-5-en-3-ol resulted in a
time dependent increase in mRNA levels of PI3K. This data was
substantiated by enhancement in the levels of p85 PI3K on treat-
ment with the same (Fig. 4a).
To assess the effect of (3b)-stigmast-5-en-3-ol on PKB/AKT acti-
vation, the phosphorylation pattern was also studied. Both the
crude and (3b)-stigmast-5-en-3-ol augmented the levels of phos-
pho-AKT as shown in Fig. 4a. The next proximal kinase, PKCa
was also analysed using RT-PCR. The crude as well as (3b)-stig-
mast-5-en-3-ol were able to signiﬁcantly increase the mRNA levels
at 24 h (p < 0.05) as indicated in Fig. 2. Collectively, our data dem-
onstrates that the crude extract and (3b)-stigmast-5-en-3-ol acti-
vates the insulin receptor, insulin receptor substrate-1, followed
by the activation of the downstream kinases like PI3K, AKT and
PKC a, which accounts for their anti-diabetic potential.3.3. Translocation of GLUT4 from light microsomes to plasma
membrane by (3b)-stigmast-5-en-3-ol
To check whether the increase in glucose uptake by (3b)-stig-
mast-5-en-3-ol is attributable to the translocation of GLUT4 from
lightmicrosomes (LM) to plasmamembrane (PM), the translocationFig. 3. (a) Effect of Adathoda vasica ethyl acetate extract and (3b)-stigmast-5-en-3-ol on
(100 nM), Rosiglitazone (50 lM), crude (1 lg/mL) or pure (100 ng/mL) at indicated time p
sepharose beads with phospho-speciﬁc antibodies followed by western blot as mentioned
and Insulin treated cells. Lanes 4 & 5 and 6 & 7 indicate 18 h and 24 h of Adathoda v
respectively. IR-b and IRS-1 protein expression were shown as immunoblot. (b) Semi-qua
vasica ethyl acetate extract and (3b)-stigmast-5-en-3-ol. The signaling intensities were q
depicted here. (*), P < 0.05 as compared with untreated control group.pattern was studied qualitatively, using confocal microscopy and
semi-quantitatively determined by measuring the amount of
GLUT4 in LM and PM using immunoblot. At earlier time points
(Insulin-5 min, 6 h treatments with Rosiglitazone, A. vasica crude
extract and (3b)-stigmast-5-en-3-ol), lack of detectable ﬂuores-
cencewas noticed suggesting low levels of GLUT4. At 12 h, the pres-
ence of GLUT4 is localized near the nucleus, which exhibits
enhanced ﬂuorescence upon treatment with crude extract and
(3b)-stigmast-5-en-3-ol. At 24 h, ethyl acetate extract, (3b)-stig-
mast-5-en-3-ol, Rosiglitazone and insulin (15 min) showed in-
creased ﬂuorescence through out the cell (Fig. 5).
Fig. 6a explains the translocation pattern of GLUT4 protein in
response to crude and (3b)-stigmast-5-en-3-ol from LM to PM.
Our results revealed that (3b)-stigmast-5-en-3-ol signiﬁcantly aug-
mented GLUT4 protein in PM content (p < 0.01) like the ethyl ace-
tate crude extract. The translocation pattern was comparable with
that of the positive control, insulin. Semi-quantitative analysis is
illustrated in Fig. 6b.3.4. Inhibition of Insulin receptor and PI3K blocks the glucose uptake
mechanism
To conﬁrm whether (3b)-stigmast-5-en-3-ol enhances glucose
transport the same way as insulin, the involvement of insulin
receptor and PI3K was further checked using inhibitor studies. As
shown in Fig. 7a, pretreatment with genistein (speciﬁc inhibitor
for Insulin receptor tyrosine kinase [16]) followed by incubation
with ethyl acetate extract or (3b)-stigmast-5-en-3-ol resulted in
decrease in glucose uptake up to 67.20 ± 7% and 49.68 ± 3% respec-
tively. Likewise, pretreatment with wortmannin (a speciﬁc PI3K
inhibitor [17]) and subsequent incubation with ethyl acetate ex-protein expression of pIR-b and pIRS-1. L6 myotubes were incubated with Insulin
oints for each marker. Whole cell lysates were immunoprecipitated using Protein A
in the methods section. Lanes 1–3 indicates untreated cells (control), Rosiglitazone
asica ethyl acetate extract treated cells and (3b)-stigmast-5-en-3-ol treated cells
ntitative analysis of pIR-b, pIRS-1 protein expression upon treatment with Adathoda
uantiﬁed arbitrarily. Bars represent mean of ±S.E., n = 3 and a representative blot is
Fig. 4. (a) Effect of Adathoda vasica ethyl acetate extract and (3b)-stigmast-5-en-3-ol on protein expression of p85 PI3K and pAKT. L6 myotubes were incubated with Insulin
(100 nM), Rosiglitazone (50 lM), crude (1 lg/mL) or pure (100 ng/mL) at indicated time points for each marker. Whole cell lysates were immunoprecipitated using Protein A
sepharose beads with phospho-speciﬁc antibodies followed by western blot for pAKT protein expression whereas for p85 PI3K whole cell lysates were used for western blot.
Lane 1 indicates untreated cells (control) and Lane 2 indicates Insulin treated cells. Lanes 3–8 indicate 12 h,18 h and 24 h of Adathoda vasica ethyl acetate extract treated cells
and (3b)-stigmast-5-en-3-ol treated cells respectively. b-actin and AKT served as loading control for protein expression of p85 PI3K and pAKT respectively. (b) The signaling
intensities of p85 PI3K, pAKT protein expression upon treatment with Adathoda vasica ethyl acetate extract and (3b)-stigmast-5-en-3-ol were quantiﬁed arbitrarily. Bars
represent mean of ±S.E., n = 3 and a representative blot is depicted here. (*), P < 0.05 as compared with untreated control group.
Fig. 5. Confocal immunoﬂuorescence microscopy of FITC tagged GLUT4 in skeletal muscle cells. L6 cells (treated) were ﬁxed onto coverslips using 3.7% formaldehyde and
permeabilized with 0.01% Triton X-100. The cells were then labeled with anti-goat GLUT 4 primary antibody and after subsequent washing with 1X PBS, ﬂuorescence stained
with donkey anti-goat IgG-FITC secondary antibody. The coverslips after thorough washing were mounted on the slides using Mowiol for confocal microscopy. Panel (a) refers
to untreated cells and panel (b and c) indicates the ﬂuorescence pattern of the cells treated with Insulin for 5 min and 15 min respectively. (d–f), (g–i) and (j–l) represents the
cells treated with 6 h, 12 h and 24 h of Rosiglitazone, Adathoda vasica ethyl acetate extract and (3b)-stigmast-5-en-3-ol respectively. 600 magniﬁcation.
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Fig. 6. (a) GLUT4 translocation pattern of the cells treated with Adathoda vasica ethyl acetate extract and (3b)-stigmast-5-en-3-ol using subcellular membrane fractions.
Serum-starved L6 myotubes were treated with Insulin for 15 min, crude and pure for 24 h, followed by sub-cellular membrane fractionation as mentioned in the methods
section. The resultant LM and PM fractions were immunoblotted with anti-GLUT4 antibody and the translocation pattern analyzed. Total GLUT4 content were also shown. (b)
Representative densitometry analysis of GLUT4 translocation. The signaling intensities of GLUT4 protein expression in LM & PM were detected and quantitated using
densitometric scanning. The signaling intensities were quantiﬁed arbitrarily and the data was expressed as percentage over control. Bars represent mean of ±SE., n = 3 and a
representative blot is depicted here. (**), P < 0.01 as compared with untreated control group.
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glucose uptake of up to 50.67 ± 3% and 41.35 ± 6% respectively, as
shown in Fig. 7b.4. Discussion
Skeletal muscle is one of the key insulin targeted tissue in main-
taining whole body glucose homeostasis, through the stimulation
of glucose uptake mediated by GLUT4 translocation [25]. L6 myo-
tubes is a well established skeletal muscle model for studying glu-Fig. 7. Glucose uptake patterns of Adathoda vasica ethyl acetate extract and (3b)-
stigmast-5-en-3-ol in presence of Genistein-IRTK inhibitor (a) and Wortmannin-
PI3K inhibitor (b). L6 myotubes were treated with Genistein – 50 lM (a) and
Wortmannin – 100 nM (b), 30 min prior to the incubation with the crude (1 lg/mL),
pure (100 ng/mL) or insulin (100 nM), followed by the 2-deoxy-D-[1-3H] glucose
uptake assay. The results were expressed as percentage of glucose uptake with
respect to the vehicle control. The values are mean of ±S.E., n = 3 in duplicates. (*),
P < 0.05 as compared with vehicle control group.cose uptake process [23] and hence used for the present study.
Plant derived natural compounds have established a platform for
developing new drug synthesis with fewer side effects [26].
Our study demonstrates the anti-diabetic effect of the ethyl ace-
tate extract and (3b)-stigmast-5-en-3-ol of A. vasica in vitro. Both
the ethyl acetate extract and the (3b)-stigmast-5-en-3-ol were able
to stimulate basal glucose uptake in differentiated L6 cells (Fig. 1).
Basal but not insulin-mediated glucose uptake was checked, to en-
sure that (3b)-stigmast-5-en-3-ol behaves like insulin-mimetic
compound, and not insulin-sensitizer. Previous reports on the eth-
anolic extracts from the leaves of A. vasica showed hypoglycemic
activity after oral administration in rats and rabbits [9]. Since glu-
cose uptake is the primary requisite for maintaining glucose
homeostasis, this study could better explain the mechanism be-
hind the hypoglycemic activity of the leaves of A. vasica. Further-
more, recent studies on (3b)-stigmast-5-en-3-ol have shown an
increase in glucose uptake of around 1.4 fold [12] in L6 myotubes.
Our study showed the increase in glucose uptake of up to 1.2 fold
at a much lower concentration. In comparison with the crude ex-
tract, (3b)-stigmast-5-en-3-ol exhibited a ten-fold enrichment of
glucose uptake activity (the optimum concentration of crude ex-
tract and (3b)-stigmast-5-en-3-ol was 1 lg/mL and 100 ng/mL
respectively).
To unravel the molecular mechanism of ethyl acetate extract
and (3b)-stigmast-5-en-3-ol in enhancing glucose transport, their
effect on insulin signaling cascade was examined. Jung and
co-workers [27] have proven that triterpenoids can act as insu-
lin-mimetics by activating IR-b, IRS-1 and GLUT4 translocation.
Similarly, our study was designed to prove whether (3b)-stig-
mast-5-en-3-ol could serve as a potent insulin-mimetic compound
in insulin resistant conditions. Alteration in the level of IR or de-
fects in its signal transduction pathway have been found in dia-
betic patients associated with decreased levels of IR-b, IRS-1 and
PI3K [28,29]. Both the ethyl acetate extract and (3b)-stigmast-5-
en-3-ol were able to restore IR-b and IRS-1 tyrosine phosphoryla-
tion in L6 myotubes (Fig. 3a). In the present study, the activation
of glucose uptake was strongly inhibited by genistein upon treat-
ment with the ethyl acetate extract and (3b)-stigmast-5-en-3-ol,
suggesting that glucose transport is dependent on the involvement
of the insulin receptor.
Many reports emphasize that PI3K plays a major role in insulin
signaling pathway, and regulates insulin-mediated glucose trans-
port [30]. Pretreatment with speciﬁc PI3K inhibitor (wortmannin)
resulted in a decline in the glucose uptake activity of the ethyl
acetate extract and (3b)-stigmast-5-en-3-ol, suggesting the
108 S. Sujatha et al. / International Journal of Diabetes Mellitus 2 (2010) 101–109involvement of PI3K in enhancing glucose transport. To substanti-
ate the above ﬁnding, gene level and protein level expressions
were also examined. The enhancement of PI3K expression (mRNA
as well as p85 PI3K) on treatment with ethyl acetate extract and
(3b)-stigmast-5-en-3-ol proves the involvement of PI3K in insulin
signaling cascade.
(3b)-stigmast-5-en-3-ol -induced anti-proliferation in human
leukemia cells is mediated by promoting spindle microtubule
dynamics through the Bcl-2 and PI3K/Akt signaling pathways
[10], which coincides well with the increment in PI3K and pAKT
levels upon treatment with (3b)-stigmast-5-en-3-ol in our study.
There is a clear picturisation of the signaling events occurring in
skeletal muscle in augmenting glucose uptake. To determine the
engagement of the other downstream protein kinase, the role of
PKCa was examined. The increase in PKCa on treatment with the
extract and (3b)-stigmast-5-en-3-ol concurs with the existing liter-
ature in bringing about effective glucose transport in rat skeletal
muscle cells [31].
The next important target under investigation is GLUT4, which
is the major insulin responsive glucose transporter in skeletal mus-
cle cells. The gene expression studies revealed the enhancement of
GLUT4 levels upon treatment with the ethyl acetate extract and
(3b)-stigmast-5-en-3-ol and is responsible for the increment in
glucose uptake. Similar ﬁndings were reported on the glucose up-
take activity of cinnamic acid which is attributed by the increased
expression of GLUT4 in L6 myotubes [32]. Insulin resistance is
found to be associated with impairment of GLUT4 translocation
from internal pool to the plasma membrane in skeletal muscles
[1]. Confocal analysis revealed the presence of GLUT4 around the
nucleus at 12 h and at 24 h ﬂuorescence was observed throughout
the cells. This is due to the complete redistribution of FITC tagged
GLUT4 throughout the cytoplasm. A clear picture of GLUT4 translo-
cation from the intracellular pool to the plasma membrane could
be evidenced if more sensitive cell lines like L6 GLUT4myc myo-
blasts or 3T3-L1 adipocytes were used. However, an increase in
the intensity of ﬂuorescence was observed, which clearly denotes
the increment of GLUT4 in the cells incubated with ethyl acetateFig. 8. Schematic diagram explaining the possible mechanism of action of (3b)-
stigmast-5-en-3-ol. (3b)-stigmast-5-en-3-ol exerts its anti-diabetic effect through
activation of cellular targets including IR, IRS-1, PI3K, PKC and GLUT4 of insulin
pathway resulting in enhanced glucose transport in L6 myotubes.extract and (3b)-stigmast-5-en-3-ol. We have also analysed the
GLUT4 translocation using sub-cellular membrane fractionation
and western blot. The ethyl acetate extract and (3b)-stigmast-5-
en-3-ol were able to translocate GLUT4 from the intracellular pool
to the plasmamembrane on a par with the positive control, insulin.
The presence of cycloheximide (a protein synthesis inhibitor) pre-
vented the glucose uptake stimulated by crude extract and (3b)-
stigmast-5-en-3-ol (data not shown), thereby indicating that the
increased glucose uptake is primarily due to the increased GLUT4
protein synthesis only. Another report indicated that the transloca-
tion of GLUT4 to the plasma membrane by troglitazone on L6 myo-
tubes is responsible for glucose uptake efﬁcacy [15], and well
supports our data. Collectively, these results indicate that (3b)-
stigmast-5-en-3-ol induced glucose transport is mediated in a
PI3K dependent manner on L6 myotubes. Our study is the ﬁrst to
unravel the molecular mechanism of (3b)-stigmast-5-en-3-ol by
studying its effect on key targets in insulin signaling (IR-b, IRS-1,
PI3K, AKT, PKC & GLUT4), which elucidates the anti-diabetic prop-
erty in vitro. (3b)-stigmast-5-en-3-ol was found to be non-toxic in
L6 myoblasts which was determined by the lactate dehydrogenase
release (data not shown). Moreover, (3b)-stigmast-5-en-3-ol is nei-
ther genotoxic nor cytotoxic and recommended safe for therapeu-
tic use [33].5. Conclusion
We have displayed the possible mechanism underlying the
anti-diabetic activity of (3b)-stigmast-5-en-3-ol in L6 myotubes
(Fig. 8). Our study is the ﬁrst to demonstrate the activation of
IR-b, IRS-1, PI3K, AKT/PKB, PKCa and GLUT4 by (3b)-stigmast-5-
en-3-ol in augmenting glucose transport in rat skeletal muscles.
Moreover, the restoration of glucose uptake activity by (3b)-stig-
mast-5-en-3-ol is evidenced without the stimulation of insulin,
suggesting that insulin-like property is a/the mechanism underly-
ing the anti-diabetic activity of (3b)-stigmast-5-en-3-ol in vitro.
Overall, our results suggest that (3b)-stigmast-5-en-3-ol may have
therapeutic effects in improving insulin resistance, in addition to
its cholesterol lowering effects.
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